Venetoclax is a treatment option in pediatric r/r AML and ALL, especially when specific genomic profiles are present (e.g., hypodiploid, KMT2A-, and TCF3-rearranged ALL) [2]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.